Stroke Trials Registry

Dalteparin
Fragmin®

Action
Low molecular weight heparin

Status
Approved by the US FDA for prevention of deep venous thrombosis. Phase III trial (HAEST) for prevention of stroke recurrence in patients with atrial fibrillation reported no difference from aspirin, 4/00.

Trial(s)
= Ongoing
= Completed

HAEST Heparin in Acute Embolic Stroke Trial

Web Links and Publications

Dalteperin Patient Information (MEDLINEplus).

Pharmacia Web Site.

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke (Cochrane Review).
Cochrane Database Syst Rev. 2001;4:CD000119.

Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischaemic stroke.
Cochrane Database Systematic Review. 2000;2:CD000119.

Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Lancet 2000 Apr 8;355(9211):1205-10

UID: 93